PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 30, 2025Expert Review of Clinical Immunology0 citations

Peritoneal immunity in decompensated cirrhosis

View Full Paper
OIOluwatomi Ibidapo-ObeMRMichael RooneyTBTony Bruns

Key Points

  • Decompensated cirrhosis alters peritoneal immunity, increasing the risk of infections.
  • Complications such as spontaneous bacterial peritonitis stem from immune dysfunction in the peritoneal cavity.
  • Peritoneal macrophages, T cells, and neutrophils exhibit chronic activation linked to inflammation.
  • Targeting immune cell activation may provide strategies to reduce infections and manage inflammation.

Abstract

In patients with cirrhosis and ascites, failure of intestinal barriers and cirrhosis-associated immune dysfunction contribute to the translocation of bacteria and microbial products to the peritoneal cavity, which promotes infection, perpetuates inflammation and accelerates acute-on-chronic liver failure. Resident peritoneal immune cells are repeatedly exposed to bacterial products and their activation status is linked to complications of spontaneous bacterial peritonitis. This narrative review summarizes the recent research on human peritoneal immunity in decompensated cirrhosis focusing on the altered composition and functional states of human peritoneal macrophages, resident and migrating T cells, and neutrophils and their involvement in peritoneal inflammation and infection. Peritoneal immune cells in decompensated cirrhosis show compartmentalized chronic activation and dysfunction, contributing to inflammation and infection risk. Given the direct accessibility of these cells, targeting peritoneal macrophage priming and differentiation, innate immune memory, inflammatory mediators and intercellular peritoneal cross-talk offer potential strategies to prevent infections and mitigate inflammation. To fine-tune the delicate balance between hyperinflammation and anergy, further research is necessary to translate immunomodulatory approaches into effective clinical interventions.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ibidapo-Obe et al. (2025) studied this question.

synapsesocial.com/papers/68dc261d8a7d58c25ebb2b8fhttps://doi.org/10.1080/1744666x.2025.2565670
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Functions of natural killer cells2008 · 3,902 citations
  2. 2Induction of murine peritoneal gamma/delta T cells and their role in resistance to bacterial infection.1993 · 135 citations
  3. 3Innate immune cells in cirrhosis2020 · 203 citations
  4. 4The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection2016 · 52 citations
  5. 5Pathological neutrophil migration predicts adverse outcomes in hospitalized patients with liver cirrhosis2022 · 16 citations